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Fig. Risk-adjusted mortality based on age and ﬁrst dialysis access.
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dicted mortality and then to calculate odds ratios (OR).
Results: There were 343,645 patients in this cohort:
331,217 underwentNCS and 12,428 underwent cardiac sur-
gery. BB lowered the OR for mortality signiﬁcantly on NCS
patients with 3 to 4 cardiac risk factors (OR, 0.64; 0.46-
0.90). It had no effect on patients with 1 or 2 risk factors.
However, BB resulted in a signiﬁcantly higher chance of death
in NCS patients (OR 1.17; 1.04-1.31) with no risk factors.
Conclusions: In this large series, BB appears to be
beneﬁcial perioperatively in NCS patients with high cardiac
risk. However, the use of BB in NCS patients with no car-
diac risk factors should be avoided because of the increased
chance of death seen in this patient cohort.
Author Disclosures: P. Almenoff: Nothing to disclose;
R. Freyberg: Nothing to disclose; M. Friedell: Nothing
to disclose; C. VanWay: Nothing to disclose.
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Objectives: Wound complications (WCs) negatively
impact lower extremity (LE) arterial reconstruction out-
comes. Acticoat Absorbent (Smith & Nephew, Inc) is a
moisture-absorbing alginate coated with nanocrystalline sil-
ver that delivers a sustained (3-day) dose of broadly antimi-
crobial silver ions. Via an investigator initiated clinical trial,
we tested the hypothesis that this silver-eluting topical sur-
gical dressing would lower WC rates in patients undergo-
ing open arterial LE procedures.
Methods: The study block-randomized 500 patients at
three institutions to standard gauze or silver alginate dress-
ings placed over incisions after LE arterial surgery. This orig-
inalORdressing remained until gross soiling, clinical need to
remove, or postoperative day 3 (whichever ﬁrst); subsequent
care was at provider discretion. The primary end point was
30-day WC incidence based on National Surgical Quality
Improvement Program guidelines. Demographic, clinical,
quality of life, and economic end points were also collected.
Results: Participants (70% male, 84% white; 45% with
diabetes; 31% with claudication [remainder critical limb
ischemia/aneurysm/revision]) had an overall 30-dayWC inci-
dence of 28%, with superﬁcial surgical site infection as themost
common (Table). In intent-to-treat analysis, silver alginate had
no impact on WC. In multivariable analysis, female sex (odds
ratio [OR], 1.6; 95% conﬁdence interval [CI], 1.04-2.58, P
¼ .034), ipsilateral incision length in cm (OR, 1.02; 95% CI,
1.01-1.03; P ¼ .002), and Coumadin (OR, 1.7; 95% CI,
1.02-2.85; P¼ .043) were signiﬁcantly associated with WCs.
Conclusions: The incidence of WCs remains high in
contemporary open LE arterial surgery. Under the study
conditions, a silver-eluting dressing had no effect on WC
incidence.Table. Worst wound complication by assigned dressing
Sterile SilverWound Status Ngauze alginate Totalo. (%) No. (%) No. (%)No wound complication 179 (72) 181 (72) 360 (72)
Hematoma, seroma, lymphatic complication 15 (6) 10 (4) 25 (5)
Dehiscence requiring local wound care 18 (7) 22 (9) 40 (8)
Superﬁcial surgical site infection 30 (12) 28 (11) 58 (12)
Deep surgical site infection 8 (3) 9 (4) 17 (3)
Total 250 250 500Author Disclosures: N. R. Barshes: Nothing to disclose;
M. Belkin: Nothing to disclose; A. D. Hamdan: Nothing
to disclose; N. D. Hevelone: Nothing to disclose; L. L.
Nguyen: Nothing to disclose; C. K. Ozaki: Smith &
Nephew, research grants; Novartis Institutures for
Biomedical Research, research grants; M. C. Wyers:
Nothing to disclose.
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Objectives: Risk of death in dialysis patients is lowest
with arteriovenous ﬁstulas (AVFs), followed by arteriove-
nous grafts (AVGs) and then intravenous hemodialysis
catheters (IHCs). Our aim was to analyze the effect of
age on ﬁrst dialysis access outcomes.
Methods: All patients aged $18 years in the United
States Renal Data System (2006-2010) were analyzed.
Spline modeling and risk-adjusted Cox proportional hazard
models were used to analyze the effect of age on mortality
for ﬁrst dialysis access with AVF vs AVG vs IHC.
Results: The study analyzed 502,380 patients (63 6
15 years, 57% male, 41% mortality, followup 1.6 6 1.4
years). Increasing age was a signiﬁcant predictor of overall
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Compared with patients with IHC (N ¼ 419,009), overall
risk-adjusted mortality was lowest in patients with AVF (N
¼ 71,328; HR, 0.65; P < .001), followed by AVG (N ¼
17,544; HR, 0.83; P < .001). AVF was superior to IHC
and AVG for all age groups (P < .001; Fig 1). However,
there was a signiﬁcant change in the relative efﬁcacy of
AVG at age 45 based on spline modeling: there were no
differences comparing AVG to IHC for patients aged 18
to 44 years (adjusted HR, 0.90; P ¼ .12), but AVG was su-
perior to IHC for patients aged $45 years (adjusted HR,
0.82; P < .001).
Conclusions: Contrary to previous reports, our data
suggest that AVF is superior to AVG and IHC regardless
of patient age, including in octogenarians. In contrast,
the mortality beneﬁt of AVG over IHC may not apply to
younger age groups. All patients aged <45 years should
receive AVF for dialysis access whenever possible.
Author Disclosures: I. Arhuidese: Nothing to disclose; J.
K. Canner: Nothing to disclose; J. A. Freischlag: Nothing
to disclose; N. O. Glebova: Nothing to disclose; C. W.
Hicks: Nothing to disclose; M. B. Malas: Nothing to
disclose; U. Qazi: Nothing to disclose.
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Objectives: Dialysis access-associated steal syndrome
(DASS) complicates arteriovenous (AV) access surgery.
We describe our 10-year experience with DASS.
Methods: DASS operations were retrospectively
reviewed from July 2003 to July 2013. Demographics, symp-
toms, surgical details, and outcomes were collected. IRB
approvalwas secured, and aP< .05was considered signiﬁcant.
Results: A total of 201 patients had 218 episodes of
DASS. Mean age was 65 years, 62% were female. DASS
was caused by 175 AV ﬁstulas (80%), 41 prosthetic grafts
(19%) and two thigh grafts (1%); 87% were brachial artery
based. Twenty-two percent were referred for DASS from
other practices. All patients had grade 2 (48%) or 3 (52%)
DASS. Ninety-two percent (185) were available for follow-
up, with amedian follow-up of 23 days. There were no differ-
ences in preoperative comorbidities. Surgical managements,Table. Dialysis access-associated steal syndrome (DASS) surgi
Procedure No.
Grade
3 steal (%)
Time to
intervention
Ligation 73 67 39a
Distal revascularization & interval ligation
(DRIL)
59 64 210
Revision using distal inﬂow (RUDI) 21 19a 72
Banding 38 32a 24a
Proximalization of arterial inﬂow (PAI) 12 33 92
Radial artery ligation (RAL) 13 39 199
Total 216 52 72
aP < 0.05 vs DRIL.omitting thigh grafts due to low numbers, were compared
(Table). The 30-day complications included continued steal,
thrombosis, bleeding, infectious, or mortality. During the
study period, access volume increased from 1312 access cre-
ations for 2003-2008 to 1975 for 2008-2013. Percentage of
ﬁstulas (79% vs 86%), incidence of steal (4% vs 6%), and per-
centage of distal revascularization-interval ligation (DRIL)
procedures (25% vs 28%) was consistent across study periods.
Conclusions: DRIL and ligation were performed in
the most severe patients. Compared with ligation, DRIL
has equal symptom resolution, no increase in complica-
tions, and ﬁstula preservation. Compared with banding,
DRIL resulted in superior ﬁstula preservation and fewer
complications. DRIL should be considered the gold stan-
dard management for DASS.
Author Disclosures: E. D. Dillavou: Nothing to disclose;
N. Gupta: Nothing to disclose; A. E. Leake: Nothing to
disclose; S. A. Leers: Nothing to disclose; M. S. Makar-
oun: Nothing to disclose; D. G. Winger: Nothing to
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Background: Current synthetic grafts have high rates
of failure, due primarily to thrombosis and intimal hyper-
plasia. We have developed a tissue-engineered vascular
graft that consists of human extracellular matrix and is
similar in strength to native human vein and artery. This
investigational graft is currently in clinical studies for eval-
uation of safety and efﬁcacy in hemodialysis vascular access
in patients with end-stage renal disease. In this presenta-
tion, we describe the development, preclinical experience,
and early human implant experience for these tissue-engi-
neered vascular grafts.
Technical description: A video is presented on the
ﬁrst case in the United States in which a human tissue-engi-
neered vascular graft was implanted into a patient for he-
modialysis access. Perspective is presented on the key
developmental milestones that led to the ﬁrst clinical im-
plantation. These milestones include graft growth, animalcal outcomes
(days)
Native
AVF (%)
Fistula
preserved (%)
Improvement
of steal symptoms (%)
30-day
complications (%)
64a 0a 93 10
97 100 98 14
100 95 89 37
71a 89 75a 49a
83 100 100 44
100 100 100 0
80 64 90 22
